Table 2.
Progression-free survival (PFS) and overall survival (OS) stratified by histopathological subtype
Histopathological subtype | PFS [months] (95% CI) | OS [months] (95% CI) | 5-year OS Rate |
---|---|---|---|
LMS | 15 (7.7–22.3) | 43 (25.7–60.3) | 29.0% ± 8.0% |
LG-ESS | 38 (9.3–66.7) | 150 (83.4–217.1) | 69.0% ± 18.0% |
HG-ESS | 5 (0–23.6) | 6 (0–29.5) |
95% Confidence Interval
LMS Leiomyosarcoma, LG-ESS low-grade endometrial stromal sarcoma, HG-ESS high-grade ESS, UUS undifferentiated uterine sarcoma